- Home
- SNTI vs BEDU Comparison
SNTI vs BEDU Comparison
Compare SNTI & BEDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- BEDU
- Stock Information
- Founded
- SNTI 2016
- BEDU 1994
- Country
- SNTI United States
- BEDU United Kingdom
- Employees
- SNTI N/A
- BEDU N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- BEDU Other Consumer Services
- Sector
- SNTI Health Care
- BEDU Real Estate
- Exchange
- SNTI Nasdaq
- BEDU Nasdaq
- Market Cap
- SNTI 50.3M
- BEDU 54.0M
- IPO Year
- SNTI N/A
- BEDU 2017
- Fundamental
- Price
- SNTI $1.70
- BEDU $1.73
- Analyst Decision
- SNTI Strong Buy
- BEDU
- Analyst Count
- SNTI 2
- BEDU 0
- Target Price
- SNTI $8.50
- BEDU N/A
- AVG Volume (30 Days)
- SNTI 511.1K
- BEDU 1.4K
- Earning Date
- SNTI 08-12-2025
- BEDU 08-08-2025
- Dividend Yield
- SNTI N/A
- BEDU N/A
- EPS Growth
- SNTI N/A
- BEDU N/A
- EPS
- SNTI N/A
- BEDU N/A
- Revenue
- SNTI N/A
- BEDU $224,321,752.00
- Revenue This Year
- SNTI N/A
- BEDU N/A
- Revenue Next Year
- SNTI $150.00
- BEDU N/A
- P/E Ratio
- SNTI N/A
- BEDU N/A
- Revenue Growth
- SNTI N/A
- BEDU N/A
- 52 Week Low
- SNTI $1.52
- BEDU $1.35
- 52 Week High
- SNTI $16.94
- BEDU $2.41
- Technical
- Relative Strength Index (RSI)
- SNTI 29.96
- BEDU 45.05
- Support Level
- SNTI $1.86
- BEDU $1.76
- Resistance Level
- SNTI $2.12
- BEDU $1.91
- Average True Range (ATR)
- SNTI 0.15
- BEDU 0.05
- MACD
- SNTI 0.00
- BEDU -0.01
- Stochastic Oscillator
- SNTI 0.00
- BEDU 0.00
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About BEDU Bright Scholar Education Holdings Limited each representing four
Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom (the UK) and the United States (the U.S.) Kingdom. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.